Exelixis Inc Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
Exelixis Inc (EXEL) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $137.78 million for the 12-month period ending 2012-12-31, per its 10-K filed 2015-03-02.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2015-03-02
- Exelixis Inc adjustments to additional paid in capital, equity component of convertible debt for fiscal 2012 was $137.78M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 0 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 0 month as first filed | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|
| 2012-12-31 | $137.78M 10-K · filed 2015-03-02 | ||
| 2012-08-14 | $4.90M 10-K · filed 2015-03-02 | $4.70M 10-Q · filed 2012-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |